Project Grant R01DK140937
Award Date
7/1/25
Completion Date
4/30/30
Dollars Obligated
$830K
Similar Awards
This Project Grant award of $462,000 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support research to investigate the effects of Ubiquitin D (UBD) variants on Apolipoprotein L1 (APOL1)-mediated kidney injury. The research will be conducted by Albert Einstein College of Medicine in Bronx, NY and aims to delineate the mechanisms by which a specific UBD...
This $223,176 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research on the impact of APOL1 copy number variations (CNVs) on kidney disease susceptibility in African Americans. The award recipient, Beth Israel Deaconess Medical Center (BIDMC), will develop computational approaches to characterize the risk variant architecture of APOL1 CNVs and determine the...
This Project Grant award of $777,336.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research aims to define the molecular mechanism of gut inflammation and barrier dysfunction in people with HIV (PWH). The overarching goal is to understand how HIV infection and antiretroviral therapy (ART) impact gut barrier integrity, with a focus on the role of the CARD8 inflammasome. The research will...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $133,500 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to Boston Medical Center Corporation (BMC) with a start date of September 1, 2024 and end date of August 31, 2026. The grant will fund research on the relationship between APOL1 genotypes and biomarkers of immune activation and tubular injury in the context of chronic kidney disease (CKD) in sub-Saharan...
This $820,119 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research focused on elucidating the mechanobiological functions of novel cytoskeletal structures in podocytes to reveal new therapeutic opportunities for kidney glomerular diseases. The primary research aims to better understand the mechanisms underlying podocyte homeostasis,...
This $400,000 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to understand the earliest events in podocyte injury in collagen IV nephropathies. The goal is to investigate how processing of mutant collagen IV proteins injures podocytes at early stages, leading to chronic kidney disease and renal failure. The research uses...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to the Augusta University Research Institute, Inc. (doing business as Georgia Health Sciences) will support $2,282,280 in research over the period from August 2024 to May 2028. The grant will fund investigations into the role of HIV-derived proteins, CD4+ T cells, and the protein podocan-like protein 1 (PODNL1) in the development of pulmonary vascular disease (PVD) among...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $297,302 to the University of Miami to investigate the role of the apolipoprotein M (APOM)/sphingosine-1-phosphate (S1P) signaling axis in podocyte injury and glomerular diseases. The key objectives are to: 1) determine if glomerular APOM deficiency correlates with activation of S1P/S1P receptor...
This $780,853 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research at the University of Pittsburgh examining the impact of a glucagon-like peptide-1 receptor agonist on SIV/HIV pathogenesis and antiretroviral therapy (ART) in people living with HIV. Key objectives include assessing changes to T-cell and macrophage metabolism, immune...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $199,999 to the University of Florida to develop innovative artificial intelligence (AI)-based methods to support the discovery of potent, orally available small-molecule heparanase inhibitors. The goal is to evaluate these novel heparanase inhibitors in murine models as a...